MedTrace Logo

Examining the Efficacy of tDCS in the Attenuation of Epileptic Paroxysmal Discharges and Clinical Seizures

NCT02960347 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2022-08-05

No results posted yet for this study

Summary

The current study examined the feasibility of High-Definition tDCS (HD-tDCS) in reducing epileptiform activity in a 30-month-old child suffering from early onset epileptic encephalopathy. HD-tDCS was administered over 10 intervention days spanning two weeks including pre- and post-intervention video-electroencephalography (EEG) monitoring.

Conditions

  • Ohtahara Syndrome

Interventions

DEVICE

High-definition (HD) transcranial direct current stimulator, HD-tDCS with 4x1 HD adaptor

Non-invasive focal neuromodulation

Sponsors & Collaborators

  • The City College of New York

    collaborator OTHER

  • Herzog Hospital

    lead OTHER

Principal Investigators

  • Rena Gale, MD · Herzog Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Months
Max Age
36 Months
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2016-05-31
Completion
2016-06-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02960347 on ClinicalTrials.gov